CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech that has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, along with Vyrologix. In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications. […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn's inventories of leronlimab are building up, whether they'll ever be used is actually an open question.


While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I'm composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. The first CytoDyn post of mine, "CytoDyn: What To Do When It's Too Good to be able to Be True?", set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire employment interview which I came away with a bad viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, although the disappointment hasn't been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today's payment of $3.5 million transfers ownership of the technology and also linked intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance.... milestone payments after commencement of a level III clinical trial ($1.5 zillion) and the first new drug program approval ($5 million), as well as royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn's leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It's done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it's this individual therapy and a "broad pipeline of indications" since it puts it. I call such pipelines, "pipedots." In CytoDyn's case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Might it all be smoke and mirrors? That's a question I have been asking myself from the very beginning of the interest of mine in this particular company. Judging with the multiples of a huge number of diverse responses on listings accessible through Seeking Alpha's CytoDyn Summary webpage, I am much from alone in this question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *